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TNTRODUCTION
With improvements in supportive care measures,
he treatment-relatedmortality rate of autologous hema-
opoietic cell transplantation (HCT) has decreased to
ery low levels; the result is that the overwhelming rea-
on for treatment failure is disease recurrence. Although
roviding a purer stem cell product and developingmore
ffective posttransplantation treatment strategies might
iminish relapse rates, if autologous HCT is to become
more successful intervention, improvements in the
reparative regimen are required.
Unfortunately, the task of improving treatment is
ampered at the outset by our inability to identify the
est current approaches. Only a few randomized trials
ave compared various regimens in the setting of
llogeneic HCT. Two randomized trials, 1 in acute
yeloid leukemia (AML) and 1 in chronic myeloid
eukemia (CML), compared cyclophosphamide (CY)
nd 12 Gy of total body irradiation (TBI) with CY and
5.75 Gy of TBI [1,2]. Both showed a reduction in
elapse rates with the higher TBI dose but showed
reater treatment-related mortality. Two studies have
ompared CY/TBI with busulfan (BU) and CY—1 in
ML and a second in CML [3,4]. The AML study
uggested the superiority of CY/TBI, whereas the
ML trial showed relative equivalence. Beyond this
ery limited group of studies, almost no other ran-
omized trials of preparative regimens before alloge-
eic transplantation have been published in the last
ecade and a half. The situation is even worse for
utologous HCT. Except for the rare small, under-
owered study, there are no randomized trials of pre- p
0arative regimens before autologous HCT for leuke-
ia or lymphoma.
Although the lack of randomized trials is embar-
assing, there are some good reasons for this paucity.
irst, substantial numbers of patients are required to
dentify differences in relapse rates. For example, 220
atients per arm would be needed to have a 90%
ower to detect a decrease in relapse rates from 45%
o 30%. The challenge of ﬁnding adequate numbers
f subjects for such studies is enormous when one
onsiders the heterogeneity in patients who come to
ransplantation. This problem is compounded because
ome recurrences may be due to contamination of the
tem cell product rather than failure of the preparative
egimen, thereby diluting any treatment effect and
bscuring the interpretation of results. Finally, differ-
nces in relapse rates among the current commonly
sed regimens, according to phase II data, are gener-
lly modest; this makes randomized trials of current
egimens less appealing. If progress in autologous
CT is to be made, novel approaches are needed that
ubstantially change the effectiveness of our prepara-
ive regimens.
ADIOIMMUNOTHERAPY
One general approach to the development of im-
roved preparative regimens involves the use of tar-
eted radiotherapy. This approached is based on the
ollowing observations. First, hematologic malignan-
ies are, in general, radiosensitive. Second, nonspeciﬁc
BI is an effective component of many current pre-
arative regimens. Third, evidence from 2 random-
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Innovations in Preparative Regimens for Autologous HCT
Bzed trials and several retrospective analyses argues
hat relapse rates are less with higher doses of TBI,
lthough toxicities may be greater. Finally, radiola-
eled monoclonal antibodies provide a way of target-
ng radiation to sites of disease and away from healthy
rgans that may be the sites of excessive toxicity.
ADIOIMMUNOTHERAPY IN LYMPHOMA
On the basis of these arguments, a number of clinical
rials exploring radioimmunotherapy (RAIT) as part of a
ransplant preparative regimen have been undertaken.
urning ﬁrst to non-Hodgkin lymphoma (NHL), pio-
eering studies by Press et al. [5,6] exploring the use of
scalating doses of iodine 131 (131I)–labeled anti–B-cell
ntibodies established several important principles. First,
nd perhapsmost importantly, they showed that with the
se of radiolabeled antibodies, more radiation could be
elivered to tumor sites than to healthy organs. They
lso showed that among the different anti–B-cell anti-
odies tested, the anti-CD20 antibody tositumomab re-
ulted in the most favorable biodistribution. They fur-
her showed that, for each antibody, a speciﬁc protein
ose resulted in the best biodistribution and that it was
ore difﬁcult to target tumor tissue in patients with
assive splenomegaly or large tumor burdens. Finally, in
phase I dose-escalation trial, they found that the max-
mal tolerated dose (MTD) of radiation delivered by
31I-tositumomab was 25 Gy delivered to lung. After
ompletion of the phase I trial noted previously, a phase
I study was conducted at theMTD [7]. The outcome of
7 patients with relapsed follicular lymphoma treated on
hese studies was recently compared with the outcome of
8 patients treated with autologous HCT using conven-
ional high-dose regimens over the same time period [8].
oth before and after adjusting for all known variables,
reatment-related death was less and overall survival
OS) and progression-free survival (PFS) were superior
ith RAIT. The estimated 5-year OS and PFS were
7% and 48%, respectively, for the RAIT arm, com-
ared with 53% and 29% for the conventional high-dose
rm. Given the excellent tolerance of this approach, we
re continuing to study it as treatment for older patients
aged 60 years) with recurrent NHL. For younger
atients with recurrent NHL, we conducted a phase I/II
rial adding escalating doses of CY and VP-16 to the
TD of 131I-tositumomab [9]. This study showed that
P-16 60 mg/kg and CY 100 mg/kg could be added to
abeled antibody and resulted in an OS and PFS of 83%
nd 68%—results that seemed superior to those
chieved in a group of similar patients who underwent
ransplantation during the same period with a regimen of
imilar doses of VP-16 and CY, but with 1200 cGy of
BI instead of the radiolabeled antibody. These results
re sufﬁciently encouraging to warrant a randomized
rial to conﬁrm or refute the ﬁndings. We also reported t
B&MTn 16 patients with multiply relapsed mantle cell lym-
homa who were treated with VP-16, CY, and 131I-
ositumomab [10]. The 3-year survival was 93%, and
FS was 61%, both of which are encouraging ﬁgures for
his disease.
A number of variations on this general theme have
een explored. Nademanee et al. at the City of Hope
sed a different radionuclide and anti-CD20 antibody,
ttrium 90 (90Y)–ibritumomab [11]. They reported on
8 patients with recurrent lymphoma treated with a
ombination of this reagent plus CY and VP-16, fol-
owed by autologous HCT, and, although the fol-
ow-up was short, 17 of 18 were reported to be alive in
omplete remission up to 18 months after transplan-
ation. Vose et al. [12] have begun to study the addi-
ion of lower-dose 90Y-ibritumomab combined with a
tandard multiagent transplant preparative regimen
CNU, etoposide, cytarabine, and melphalan
BEAM). They reported excellence tolerance and a
-year OS of 78% and PFS of 60%.
AIT IN LEUKEMIA
We have conducted a series of studies of radio-
abeled antibodies for the treatment of acute leuke-
ia. In initial studies, we found that an anti-CD45
ntibody gave us the best biodistribution and that
n optimal protein dose was 0.5 mg/kg. By using
his antibody at this protein dose, approximately 3
imes more radiation could be delivered to bone
arrow and 12 times more to spleen than to liver;
he healthy organ received the highest dose. A phase
study in patients with recurrent leukemia under-
oing allogeneic HCT showed that approximately
0 Gy of radiation delivered by a radiolabeled an-
ibody could be safely added to a standard CY/TBI
egimen [13]. We subsequently completed a phase
I trial of 131I–anti-CD45 plus standard BU/CY for
atients with AML in ﬁrst remission and found a
1% PFS at 5 years, including a 69% PFS among
atients with intermediate-risk cytogenetics—re-
ults that are superior to what we have seen with
U/CY alone in a similar group of patients [14].
gain, a randomized trial will be required to test the
uperiority of this approach.
Studies of RAIT in leukemia using other radionu-
lides and antibodies targeting other antigens include
rials of 90Y–anti-CD33 and rhenium 188–anti-
D66, each combined with a standard preparative
egimen [15,16]. Each of these studies has demon-
trated that it is possible to selectively deliver radiation
o sites of leukemia, and each approach has unique
eatures that make it attractive, but data are lacking
hat carefully compare one approach with another.
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4UTURE DEVELOPMENTS IN RAIT
The attraction of RAIT is the speciﬁcity of deliv-
ry of radiation to sites of disease while sparing
ealthy organs. With RAIT as it is conventionally
elivered, the degree of speciﬁcity is diminished be-
ause early after injection virtually all of the radiola-
eled antibody circulates in the bloodstream, deliver-
ng radiation nonspeciﬁcally before binding to the
arget, and late after injection, a portion of the anti-
ody never binds to the target and also continues to
adiate nonspeciﬁcally. Two approaches have been
eveloped that can effectively remove the portion of
ntibody that fails to bind to the target. One involves
xtracorporeal antibody adsorption, and the second
ses a cleavable linker that allows the radionuclide to
e released from the antibody and rapidly excreted.
oth have been shown to work in animal models. A
hird approach that diminishes both the early and late
onspeciﬁc radiation involves initial administration of
n antibody-streptavidin conjugate, then a clearing
gent, and ﬁnally the radionuclide conjugated to bi-
tin. This pretargeting approach is able to achieve
umor–normal organ ratios of greater than 80:1 in
urine models, and thus it offers great promise for the
evelopment of improved preparative regimens for
he treatment of leukemia and lymphoma [17].
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